Shares of the Hepion Pharmaceuticals, Inc. (HEPA) stock were rising in premarket today on October 11, 2021. HEPA stock price saw a push of 2.09% to reach $1.511 a share at the time of this writing. The stock was also green in the previous trade and went up by 0.68% at closing.
Hepion Pharmaceuticals, Inc. is the biopharmaceutical stock that develops therapeutics to treat chronic liver diseases in the U.S. Its lead product candidate is CRV431 for the treatment of liver diseases. Let’s understand why this stock is rising today.
Hepion stock will participate in H.C. Wainwright’s 5th Annual NASH Investor Conference on October 12, 2021. On October 07, 2021, HEPA stock announced Dr. Todd Hobbs, who is the CMO of Hepion will present at the upcoming H.C. Wainwright 5th Annual NASH Investor Conference on Tuesday, October 12, 2021. The live broadcasting of the virtual presentation will be available on www.hepionpharma.com.
Investors are hopeful that there will be something positive from the HEPA stock in the upcoming conference and this responding positively to this penny stock. For your intuition, let’s discuss some previous events of this stock.
Drug-Drug Interaction Study of HEPA stock:
On September 29, 2021, HEPA stock did announce the results of its lead drug candidate, CRV431 in the Drug-Drug interaction study. The purpose of the study was to examine the influence of single or multiple oral doses of ketoconazole against the pharmacokinetics of CRV431 and its major metabolites. The study team also examined the effect of single or multiple once-daily oral doses of CRV431 on PK of midazolam and its metabolite, 1-hydroxymethyl midazolam.
The results of the study were according to expectations. The CRV431 maximum blood concentration rose almost five-fold while the exposure increased approximately four-fold from 24 hours dosing time. Midazolam and 1-hydroxymethyl midazolam had not shown significant alteration when CRV431 was dosed with midazolam.
Phase 2a AMBITION trial of HEPA stock:
HEPA stock on September 13, 2021, released the data from its Phase 2a AMBITION clinical trial related to the efficacy of CRV431. The data covered the additional biomarkers, alanine aminotransferase, and N-terminal type III collagen pro-peptide. The pharmacologic and bioinformatic analyses indicated that CRV431 is very much effective against Non-alcoholic steatohepatitis (NASH).
So the above story tells that momentum has been already created before the upcoming presentation of HEPA stock at H.C. Wainwright’s 5th Annual NASH Investor conference. Effective results from the DDI trial will be beneficial for future clinical trials and will help in the commercialization of the product.